| First Author | Bataller A | Year | 2019 |
| Journal | Leukemia | Volume | 33 |
| Issue | 5 | Pages | 1076-1089 |
| PubMed ID | 30816330 | Mgi Jnum | J:274252 |
| Mgi Id | MGI:6296357 | Doi | 10.1038/s41375-019-0420-1 |
| Citation | Bataller A, et al. (2019) The role of TGFbeta in hematopoiesis and myeloid disorders. Leukemia 33(5):1076-1089 |
| abstractText | The role of transforming growth factor-beta (TGFbeta) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGFbeta signaling has been described as an important pathway involved in carcinogenesis and cancer progression. In the hematopoietic compartment, the TGFbeta pathway is an important regulator of proliferation and differentiation of different cell types and has been implicated in the pathogenesis of a diverse variety of bone marrow disorders. Due to its importance in hematological diseases, novel inhibitors of this pathway are being developed against a number of hematopoietic disorders, including myelodysplastic syndromes (MDS). In this review, we provide an overview of the TGFbeta pathway, focusing on its role in hematopoiesis and impact on myeloid disorders. We will discuss therapeutic interventions with promising results against MDS. |
